Komplikationen bei Trägern kardialer implantierbarer elektronischer Devices

Die Zahl der Patienten mit kardialen implantierbaren elektronischen Geräten nimmt kontinuierlich zu. Da es sich häufig um ältere und/oder multimorbide Personen handelt, haben Notfallmediziner regelmäßig Kontakt zu diesen Patienten. Der Umgang mit diesen Devices und den assoziierten Komplikationen ist komplex. Ziel dieses Artikels ist es, einen Überblick über die aktuell verfügbare Geräte, die klinische Präsentation und mögliche Behandlungsstrategien darzustellen.

Schlüsselwörter

Herzschrittmacher - Notfallmedizin - kardiales implantierbares elektronisches Device - implantierbarer Kardioverter-Defibrillator - CIED - ICD

• Literatur

• 1 Markewitz A, Nowak B, Fröhlig G. et al. Jahresbericht 2020 des Deutschen Herzschrittmacher- und Defibrillator-Registers – Teil 1: Herzschrittmacher. Herzschr Elektrophys 2022; 33: 398-413
• 2 Bardy GH, Lee KL, Mark DB. et al. Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure. N Engl J Med 2005; 352: 225-237
• 3 Pitman BM, Schirripa V, Munawar DA. et al. Should We Check It? Assessing Interrogation of Cardiac Implantable Electronic Devices in the Emergency Department-The CHECK-ED Study: Implications for Service Planning and Care Delivery. Heart Lung Circ 2022; 31: 1119-1125
• 4 Glikson M, Nielsen JC, Kronborg MB. et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace 2022; 24: 71-164
• 5 Burri H, Starck C, Auricchio A. et al. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace 2021; 23: 983-1008
• 6 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021; 42: 3599-3726
• 7 Zeppenfeld K, Tfelt-Hansen J, de Riva M. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2022; 43: 3997-4126
• 8 Blomström-Lundqvist C, Traykov V, Erba PA. et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Europace 2019; 22: 515-549
• 9 Wiedmann F, Ince H, Stellbrink C. et al. Single beta-blocker or combined amiodarone therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator patients: Insights from the German DEVICE registry. Heart Rhythm 2023; 20: 501-509
• 10 Birnie DH, Healey JS, Wells GA. et al. Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation. N Engl J Med 2013; 368: 2084-2093
• 11 Munawar DA, Mahajan R, Linz D. et al. Predicted longevity of contemporary cardiac implantable electronic devices: A call for industry-wide “standardized” reporting. Heart Rhythm 2018; 15: 1756-1763
• 12 Brugada J, Katritsis DG, Arbelo E. et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41: 655-720
• 13 Stiles MK, Fauchier L, Morillo CA. et al. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace 2019; 21: 1442-1443
• 14 Larsen GK, Evans J, Lambert WE. et al. Shocks burden and increased mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2011; 8: 1881-1886
• 15 Bucciarelli-Ducci C, Vardas P. Reconsidering safety and reducing barriers to MRI in patients with cardiac implantable electronic devices. Eur Heart J 2021; 43: 2479-2481
• 16 Schaller RD, Brunker T, Riley MP. et al. Magnetic Resonance Imaging in Patients With Cardiac Implantable Electronic Devices With Abandoned Leads. JAMA Cardiol 2021; 6: 549-556
• 17 Thygesen K, Alpert JS, Jaffe AS. et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018; 138: e618-e651
• 18 Cai Q, Mehta N, Sgarbossa EB. et al. The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time?. Am Heart J 2013; 166: 409-413
• 19 Sgarbossa EB, Pinski SL, Gates KB. et al. Early electrocardiographic diagnosis of acute myocardial infarction in the presence of ventricular paced rhythm. GUSTO-I investigators. Am J Cardiol 1996; 77: 423-424
• 20 Smith SW, Dodd KW, Henry TD. et al. Diagnosis of ST-elevation myocardial infarction in the presence of left bundle branch block with the ST-elevation to S-wave ratio in a modified Sgarbossa rule. Ann Emerg Med 2012; 60: 766-776